Farallon Capital Management 13F, Q2 2026
Farallon Capital · quarter ending 30 June 2026 · filed 14 August 2026 · SEC CIK 909661
Common stock only: shares the fund reported owning at the quarter end, valued as filed. The filing also lists 3 put and call lines, reported at the value of the underlying shares; they are not ownership and are not in these totals.
Largest positions, Q2 2026
The 25 largest of 86 positions. Weights are against the whole filed book. Changes are in shares held, against the Q1 2026 filing.
| Company | Ticker | Value | % of book | vs Q1 2026 |
|---|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | $2.54B | 14.9% | new |
| ELECTRONIC ARTS INC | EA | $1.62B | 9.5% | +6% shares |
| BRIDGEBIO PHARMA INC | BBIO | $800.14M | 4.7% | new |
| PROTAGONIST THERAPEUTICS INC | PTGX | $778.25M | 4.6% | new |
| EXELIXIS INC | EXEL | $732.79M | 4.3% | new |
| LIQUIDIA CORPORATION | LQDA | $666.94M | 3.9% | new |
| AMAZON COM INC | AMZN | $627.55M | 3.7% | new |
| LANTHEUS HLDGS INC | LNTH | $619.43M | 3.6% | new |
| NATERA INC | NTRA | $602.18M | 3.5% | new |
| UNITEDHEALTH GROUP INC | UNH | $528.07M | 3.1% | new |
| THERMO FISHER SCIENTIFIC INC | TMO | $526.02M | 3.1% | new |
| ROIVANT SCIENCES LTD | $506.40M | 3.0% | new | |
| AON PLC | $458.58M | 2.7% | new | |
| BOSTON SCIENTIFIC CORP | BSX | $449.04M | 2.6% | new |
| BROADCOM INC | AVGO | $435.09M | 2.5% | new |
| MICROSOFT CORP | MSFT | $415.12M | 2.4% | new |
| TANGO THERAPEUTICS INC | TNGX | $383.78M | 2.3% | new |
| KKR & CO INC | KKR | $377.98M | 2.2% | new |
| SYNOPSYS INC | SNPS | $370.06M | 2.2% | new |
| BEAM THERAPEUTICS INC | BEAM | $351.31M | 2.1% | new |
| CRINETICS PHARMACEUTICALS IN | CRNX | $336.37M | 2.0% | new |
| GRAIL INC | GRAL | $284.11M | 1.7% | new |
| WABTEC | WAB | $241.16M | 1.4% | new |
| IMMUNOVANT INC | IMVT | $223.67M | 1.3% | new |
| TWIST BIOSCIENCE CORP | TWST | $219.79M | 1.3% | new |
What changed since Q1 2026
Against the Q1 2026 filing, Farallon Capital Management opened 85 new positions, added to 1, trimmed 0, left 0 unchanged and exited 0. Every position is compared, matched on its CUSIP; a change of 2% or less in shares counts as unchanged.
Other quarters
Source: SEC Form 13F-HR, accession 0000908834-26-000432, filed by FARALLON CAPITAL MANAGEMENT, L.L.C.. Values are as filed and cover US-listed positions only; a 13F does not show short positions or holdings outside the US. A 13F may be filed up to 45 days after the quarter ends, so the fund may have traded since. Educational information, not financial advice.